Cancer

Cancer

BlossomHill Therapeutics Presents Promising Findings in Phase 1/2 SOLARA Trial for BH-30643 in NSCLC Patients

BlossomHill Therapeutics, a clinical-stage biopharmaceutical company, has presented preliminary findings from the dose escalation portion of its ongoing Phase 1/2 SOLARA trial of BH-30643 in patients with locally advanced or metastatic EGFR-mutant non-small cell lung cancer (NSCLC). BH-30643 is a first-in-class, macrocyclic, non-covalent, mutant selective OMNI-EGFR inhibitor designed to